SOLV Solventum
Stable spin-off cash machine, margins normalized; about 15-25% upside, a fair discount rather than a bargain.
The story
Solventum is the 3M healthcare spin-off, a diversified med-tech portfolio (MedSurg, dental, health information systems, and purification/filtration, which is being sold) with sticky hospital consumables, entrenched brands in wound care and sterilization, and a durable HIS coding franchise. It is a mature, low-growth business still working through separation. The dip to 11.8% operating margin was a one-time separation and restructuring charge, and TTM margins have recovered to about 23.6%. The investment case rests on stable cash generation, debt paydown and modest mix improvement, not on growth.
The facts have not changed materially since August, so all drivers are held. TTM margin of 23.6% supports a 22.5% sustainable target once stranded costs and TSA exits are considered. The roughly 1% revenue CAGR justifies about 2% growth, and the net debt of 4.2B keeps beta above the 0.9 industry anchor.
Value drivers
| Revenue growth (Y1) | 2.0% |
| Terminal growth | 2.5% |
| Forecast horizon | 6y |
| Target operating margin | 22.5% |
| Years to target margin | 4 |
| Sales-to-capital | 0.85 |
| Beta | 1.10 |
| Failure probability | 2.5% |
| Cost of capital (WACC) | 8.9% |
| Terminal WACC | 8.6% |
Valuation bridge
| PV of explicit FCFF | 7.27B |
| PV of terminal value | 16.21B |
| Equity value | 18.85B |
| ÷ shares → per share | $110.73 |
News
bullish +0.20 · 8 articles
- Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
- What Solventum (SOLV)'s Earnings Beat and Surgical AI Push Means For Shareholders
- Q2 Surgical Equipment & Consumables - Diversified Earnings: Solventum (NYSE:SOLV) Impresses
- 3 S&P 500 Stocks with Open Questions
- Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
- 2 Mid-Cap Stocks to Consider Right Now and 1 That Underwhelm
- Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
- 3 Reasons to Avoid SOLV and 1 Stock to Buy Instead
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 8.48B | 2.0% | 23.3% | 1.80B | 195.51M | 1.60B | 1.47B |
| 2 | 8.65B | 2.1% | 23.1% | 1.81B | 209.39M | 1.60B | 1.35B |
| 3 | 8.84B | 2.2% | 22.8% | 1.83B | 223.96M | 1.61B | 1.24B |
| 4 | 9.05B | 2.3% | 22.5% | 1.85B | 239.30M | 1.61B | 1.14B |
| 5 | 9.26B | 2.4% | 22.5% | 1.89B | 255.44M | 1.64B | 1.07B |
| 6 | 9.50B | 2.5% | 22.5% | 1.94B | 272.47M | 1.67B | 998.88M |
Key risks
- Separation dis-synergies and ERP/TSA exit costs erode the margin recovery
- Continued volume and pricing pressure in MedSurg and dental with persistently flat revenue
- Leverage (4.2B net debt) and residual 3M-era PFAS/earplug-adjacent liability exposure
Catalysts
- Proceeds from the purification/filtration divestiture accelerate deleveraging
- Sustained ~23%+ margins confirming the post-spin cost structure plus new product launches (surgical AI, negative-pressure wound therapy)